REG - N4 Pharma PLC - Oral application update

N4 PharmaAnnouncement

17/01/2023 07:01

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230117:nRSQ8746Ma&default-theme=true

RNS Number : 8746M  N4 Pharma PLC  17 January 2023

17 January 2023

N4 Pharma Plc

("N4 Pharma" or the "Company")

 

Oral application update

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing
Nuvec®, a novel delivery system for cancer treatments and vaccines, provides
an update on its ongoing Australian Research Council grant work with the
University of Queensland, investigating the oral delivery of Nuvec® loaded
with DNA.

 

The Company has now completed two in vivo studies demonstrating that Nuvec
loaded with OVA m-cherry DNA and encapsulated within an acid protective
polymer can be dosed orally, penetrate the mucus layer and successfully
express the OVA m-cherry locally in the intestine epithelial cells.

In the first study Nuvec® was formulated together with the OVA and the whole
formulation was coated with the polymer as a capsule. In the second study the
nanoparticles, once loaded with OVA, were individually encapsulated with the
polymer and administered via an oral gavage.

 

Nigel Theobald, Chief Executive Officer of the Company, commented:

 

"These studies are at an early stage in the development of an oral
application, but show the versatility of Nuvec both in terms of its ease of
formulation and application in a wide number of areas. Having successfully
demonstrated Nuvec can be administered orally and locally transfect cells in
the intestine, the next step is to investigate what the most suitable medical
application might be for this delivery method.

 

We are greatly encouraged by these early results and look forward to
continuing the work in this area, whilst continuing with our ongoing siRNA
work."

 

Enquiries:

 N4 Pharma Plc                                          Via Scott PR

Tel +44 1477 539539
 Nigel Theobald, CEO

 Luke Cairns, Executive Director

 SP Angel Corporate Finance LLP                         Tel: +44 (0)20 3470 0470

 Nominated Adviser and Joint Broker

 Matthew Johnson/Kasia Brzozowska (Corporate Finance)

 Vadim Alexandre/Rob Rees (Corporate Broking)
 Turner Pope Investments (TPI) Limited                   Tel: +44 (0)20 3657 0050

 Joint Broker

 Andy Thacker

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery
system for cancer and vaccine treatments using its unique silica nanoparticle
delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel
antigens for cancer and vaccine treatments to use Nuvec® as the delivery
vehicle to get their antigen into cells to express the protein needed for the
required immunity. As these products progress through pre clinical and
clinical programs, N4 Pharma will seek to receive up front payments, milestone
payments and ultimately royalty payments once products reach the market.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDZZGMMDVZGFZM